321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
The Readout Loud
00:00
Introducing Ivo: A Promising Lung Cancer Treatment
This chapter features a new podcast team member while highlighting significant upcoming clinical data from Summit Therapeutics, particularly around their drug Ivo. The conversation centers on the upcoming presentation of lung cancer data and the implications of the Harmony II study results in comparison to Merck's Keytruda.
Transcript
Play full episode
